TABLE 2.

Distribution of promoter A and B methylation levels (promA and promB) across age groups and metastatic sites.

	promA			promB
	Median	IQR	P	Median	IQR	P
Age
<50	39	28–44.25	0.7213	32	21–50	0.8304
≥50	38.5	33–46.5		33	21.8–46
Liver involvement
No	41.5	34.5–50	0.0196	33.75	21–48.5	0.5009
Yes	36.5	25–38.5		28	23.3–42
Lung involvement
No	41.3	33.8–48.3	0.1498	32	21–45	0.2486
Yes	36.5	30.5–40.5		40	24–50
Bone involvement
No	41.5	36.5–46	0.1268	37.3	30.8–50	0.1017
Yes	38.5	31–41.5		26.8	20.3–44
Lymph nodes involvement
No	38.5	33–43.5	0.9625	32	21–42.5	0.2150
Yes	39.5	31–48.5		37.5	24–50
Soft tissue involvement
No	40.5	33–46.5	0.1137	32	21–42.8	0.0688
Yes	31	30.5–35.5		50	38.3–55

Methylation levels were significantly lower for promA in patients with liver involvement (P = 0.0196). Significance was tested through the Mann–Whitney U test.